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Bacterial hyaluronan lyase enzymes are the major virulence
factors that enable greater microbial ingress by cleaving hyalu-
ronan (HA) polymers present predominantly in extracellular
space of vertebrates. Based on the premise that effective inhibi-
tors may bind to and stabilize HA thereby protecting it from
degradation, here we investigated inhibitory activity of human
hyaluronan-binding protein 1 (HABP1) on bacterial hyaluroni-
dase because it is highly specific to HA and localized on the cell
surface. Biochemical characterization revealed that HABP1 is a
competitive inhibitor of Streptococcus pneumoniae hyaluronate
lyase (SpnHL) with an IC50 value of 22 M. This is thus the first
report of an endogenous protein inhibitor thatmay be used dur-
ing natural antibacterial defense. Our findings also support a
novelmultiprongedmechanism for the high efficacy of HABP1-
mediated inhibition based on structural modeling of enzyme,
substrate, and inhibitor. Evidence from docking simulations
and contact interface interactions showed that the inherent
charge asymmetry of HABP1 plays a key role in the inhibitory
activity. This novel role of HABP1may pave the way for peptide
inhibitors as alternatives to synthetic chemicals in antibacterial
research.
Bacterial hyaluronidases have long been known as the
“spreading factors” or virulence factors responsible for a wide
range of acute and invasive infections in humans causing life-
threatening diseases, such as pneumonia, meningitis, and sep-
ticemia among many others (1–3). These enzymes directly
facilitate the spread of infection by degrading the HA3 matrix,
which constitutes a highly organized network in the extracellu-
lar space in all vertebrates, acting as a diffusion barrier in vivo
and regulating the transport of other substances through the
intercellular space (4). The HAmatrix in extracellular matrix is
mainly composed ofHApolymer, a negatively charged polysac-
charide of repeating disaccharide units of D-glucuronic acid
(-1,3) and N-acetyl--D-glucosamine, and is highly viscous in
nature (5). Hyaluronidases are able to split thismatrix, reducing
its viscoelasticity and increasing membrane permeability,
thereby allowing greater microbial access to or promoting dif-
fusion between host tissues for colonization (4, 6, 7). The orga-
nized structure ofHA substantially influences binding to recep-
tors and to the active site of hyaluronidases. Bacterial
hyaluronidases, isolated from strains of various microorgan-
isms such as Clostridium,Micrococcus, Streptococcus, or Strep-
tomyces, degrade HA at very fast rates via a -elimination reac-
tion that cleaves the alternate -1,4-glycosidic linkage between
the repeating units, resulting in unsaturated disaccharide prod-
ucts (8, 9). Although the mechanism of hyaluronidase-medi-
ated degradation of HA has been very well elucidated through
biochemical as well as structural investigations (10, 11), rela-
tively little is known about the defensemechanisms used by the
host during infection or about the role ofHAandhyaluronidase
in pathophysiological processes. It is believed that the balance
of HA biosynthesis and intrinsic hyaluronidase levels may
be regulated by invoking specific inhibitors (12–14). As a result,
potent and specific inhibitors of bacterial hyaluronate lyase
would have enormous therapeutic potential as drugs in the
treatment of various bacterial infections.
The search for effective hyaluronidase inhibitors beganmore
than half a century ago (2, 15–18) and continues to this day.
Exogenous small molecule inhibitors have been identified, but
they have weak potency and low selectivity, and there are many
unanswered questions with regard to their mechanism of inhi-
bition and whether they would be active against bacterial hya-
luronidases as well. For example, heparins and derivatives of
alginic acids (19, 20) have structural similarity to HA, whereas
polyphenols, flavone analogues (21), saponins, norlignans, or
antiallergic drugs are among other reported inhibitors of hya-
luronidases (22, 23). VitaminC, L-arginine derivatives, and fatty
acids have been reported to inhibit streptococcal hyaluroni-
dases at submillimolar concentrations, but a comparison of
percent inhibition and IC50 values between these and previous
reports is difficult because of differences in the experimental
conditions (24–26). In view of the enormous medical applica-
tions of effective inhibitors, a systematic search has continued,
using computer-aided drug design strategies. A rational analy-
sis based on structural interactions led to the identification of a
hydrophobic derivative of vitamin C as a strong inhibitor of
* The costs of publication of this articlewere defrayed in part by the payment
of page charges. This article must therefore be hereby marked “advertise-
ment” in accordancewith 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by the Innovative Young Biotechnologist Award by the Depart-
ment of Biotechnology, Government of India. To whom correspondence
may be addressed. E-mail: gy@nipgr.res.in.
2 Supportedby theDepartmentof Biotechnology andDepartmentof Science
and Technology. To whom correspondence may be addressed. E-mail:
kdatta@mail.jnu.ac.in.
3 The abbreviations used are: HA, hyaluronan; HABP1, hyaluronan-binding
protein 1; SpnHL, S. pneumoniae hyaluronate lyase; a.s.a., accessible sur-
face area.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 6, pp. 3897–3905, February 6, 2009
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
FEBRUARY 6, 2009•VOLUME 284•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3897
 by guest, on August 12, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
Streptococcus agalactiaehyaluronidase, but it wasweakly active
against Streptococcus pneumoniae, a major human Gram-pos-
itive pathogen (27). Computer-aided drug design-based strate-
gies mainly explore new leads by virtue of structural similarity
to HA or, in some cases, by rational de novo approaches. An
alternative strategy may also exist wherein an inhibitor may
bind to and stabilize HA thereby protecting it from degrada-
tion. Such an alternative is plausible because HA has been
known to bind and interact with receptors and a large number
of HA-binding proteins. Hyaladherins are a very well charac-
terized and highly selective family of proteins reported to inter-
act non-covalently with HA and have a wide array of functions,
including receptor-mediated activation of intracellular signal-
ing and structural aggregations in the extracellular matrix (28–
30). We therefore began this work with the surmise that a
potent hyaluronidase inhibitor may be supplied endogenously
by one of these ubiquitous proteins. HABP1 (synonym human
p32 or gC1qR), a member of the multifunctional hyaladherin
family, is a 68-kDa protein originally purified and cloned from
human fibroblast as a novel HA receptor by our group (31). In
this work, HABP1 was tested as an inhibitor of bacterial hyalu-
ronidase because we had already confirmed its localization on
the cell surface (32). According to the crystal structure of
HABP1, it exists as a homotrimer having N-terminal -helices
and asymmetric charge distribution with structural plasticity
(33).
Here we report the role of HABP1 as an inhibitor of S. pneu-
moniae hyaluronidase (SpnHL) and the elucidation of its com-
petitive nature of inhibition. We also propose a unique multi-
pronged mechanism of action based upon evidence from
structural modeling of the interactions among substrate,
enzyme, and inhibitor. Thus we present biochemical evidence
for a novel role of HABP1 in pathophysiological processes as a
highly potent inhibitor of SpnHL, offering a variety of avenues
for optimization of selectivity and potency.
EXPERIMENTAL PROCEDURES
General Materials and Reagents—Substrate from human
umbilical cord HA was purchased from Sigma Co. All other
chemicals were of analytical grade and obtained from Sigma.
Purification and Estimation of HABP1—HABP1 (amino
acids 74–282) was overexpressed in Escherichia coli and puri-
fied following the method described earlier (34) with modifica-
tions using the 55–90% ammonium sulfate cut followed by ion
exchange chromatography on Mono QTM HR (10/10) column
(Amersham Biosciences) using a linear gradient of 0–1 M NaCl
in 20 mM Tris, pH 7.2, after washing the column with 150 mM
NaCl in 20 mM Tris, pH 7.2. The pooled peak fractions were
dialyzed in 150mMNaCl, 20mMTris, pH7.2, and quantified for
further use.
Assay of SpnHL Enzymatic Activity—The activity of SpnHL
was determined following the method described earlier (35)
and is defined as its ability to break down HA to unsaturated
disaccharide units (36). In a 1-ml solution of 0.2 mg/ml HA in
50 mM sodium acetate buffer, 10 mM CaCl2, pH 6.5, 10 l of
enzyme sample (3 ng/l, diluted just before taking measure-
ment)was added. The reactionmixturewas incubated for 5min
during which the measurements were carried out by monitor-
ing the increase in absorbance at 232 nm at 25 °C in a Cary 100
Bio UV-visible double beam spectrophotometer (Varian Inc.).
Determination of Inhibitory Activity on Hyaluronidase—The
in vitro enzyme inhibition experiments were performed with
varying concentrations of HABP1. The inhibitory effect of
HABP1 on S. pneumoniae hyaluronidase was measured by
using two different enzymatic inhibition assays. In the first
assay 0.2 mg/ml HA was preincubated with varying concentra-
tions (0–100 M) of HABP1 for 1 h at 4 °C in a l-ml reaction
volume of 50 mM sodium acetate buffer, 10 mM CaCl2, pH 6.5.
The reaction was initiated with 30 ng of enzyme, and activity
was measured. In the second assay, 30 ng of SpnHL was prein-
cubated in the abovementioned 1-ml reaction volume of buffer
with varying concentrations of HABP1 (0–100 M) for 1 h at
4 °C. The reaction was initiated with 0.2 mg/ml HA, and enzy-
matic activity was measured. In both assays, the reaction was
initiated exactly at 60 s after the addition of either enzyme or
HA, respectively, to the reaction mixture. The progress of the
reaction was monitored by detecting the appearance of HA oli-
gosaccharide at 232 nm absorbance.
Enzyme Activity in Absence and Presence of Inhibitor—To
study the effect of varying the concentration of substrate in the
presence of inhibitor, HA concentration in solution was
expressed as moles of hexasaccharide based on a hexasaccha-
ridemolecularweight of 1203.9 (37). In the absence of inhibitor,
varying concentrations of HA (0.0625–0.750 mM) in 150 mM
sodium acetate buffer, 10 mM CaCl2, pH 6.5, was added to the
enzyme (30 ng), and the activity was measured. In the presence
of inhibitor, 20 M HABP1 was preincubated with the enzyme
(30 ng) for 1 h at 4 °C in a 1-ml reaction volume of buffer,
increasing concentrations of HA (0.0625–0.750 mM) were
added, and enzymatic activity was measured exactly 60 s after
the HA was added to the reaction mixture. The progress of the
reaction was monitored by detecting the appearance of HA oli-
gosaccharide at 232 nm absorbance.
Initial Velocity Measurement and Data Analysis—The reac-
tion progress curves for the enzymatic activity and enzyme
inhibition were obtained by measurement of the absorbance at
232 nm due to the unsaturated disaccharide product. The reac-
tion was carried out in a 1-ml solution of 50mM sodium acetate
buffer, 10 mM CaCl2, pH 6.5, with substrate concentration
ranging from 0.2072 to 0.3469 mMHA in the above buffer. The
reaction was initiated by the addition of 10 l of enzyme in the
same buffer. The product absorbance was measured every 60 s
for 5 min at 25 °C. The reaction progress was linear over the
time of measurement within the precision of the instrument.
The initial velocity of the reaction was determined from the
increase in absorbance over the first 5 min of the reaction.
The slope was divided by the molar absorption coefficient for
the disaccharide product, 5.5 103 mol1 cm1 (36). The val-
ues were calculated and expressed in M/min HA degradation
by SpnHL in the presence of HABP1.
The data for initial velocity, Vi, from each experiment in
which the concentration of substrate, S, was varied, were fit into
the Michaelis-Menten equation with a nonlinear regression
program (GraphPad Prism, version 5, GraphPad Software Inc.,
San Diego, CA). For all experiments, goodness-of-fit statistics
showed that R2 and correlation values were greater than 0.987
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and 0.982, respectively. Among the curve fitting results, the
program gave values of Vmax and Km as well as their respective
standard deviations ().
Computational Simulations—The structural details of the
interactions among substrate, enzyme, and inhibitor were elu-
cidated by molecular docking experiments. Available crystal
structures of the S. pneumoniaehyaluronate lyase (ProteinData
Bank code 1LOH) and humanHABP1 (Protein Data Bank code
1P32) were used for docking studies (33). The three-dimen-
sional structures of the HA oligomers, namely disaccharide,
tetrasaccharide, and hexasaccharide, were processed from the
available crystal structure complex of SpnHL and HA hexasac-
charide (Protein Data Bank code 1LOH). Details of local non-
covalent interactions were studied using an in-house Fortran
program/script that requires an interacting complex in Protein
Data Bank format. The solvent-accessible area lost upon com-
plexation was measured using NACCESS (38). All visualiza-
tions and renderings were done using VMD (Visual Molecular
Dynamics) (39) and PyMOL (40).
Substrate Inhibitor Interaction—The three-dimensional
structure of the inhibitor (Protein Data Bank code 1P32)
having three potential active sites (one per monomer) was
treated as the static “receptor” molecule with HA polysac-
charide as themobile “ligand”molecule. The three processed
HA oligomers were docked to HABP1, one at a time, with the
experimentally characterized BX7B (where B is a basic resi-
due) HA binding motif (residues 119–128, 1P32 numbering)
defined as the binding site (31, 41). Flex-X molecular dock-
ing program was used because it is able to accurately predict
the geometry of the protein-ligand complex for a protein
with known three-dimensional structure and a small ligand
molecule. Flex-X is based on a robust incremental construc-
tion algorithm where the ligand is decomposed into pieces
and thereafter flexibly rebuilt in the active site usingmultiple
placement strategies followed by a ranking of all orientations
using a variety of scoring functions. Hydrogens were added
to both structures before the experiment. Default parameter
values were used, and the top ranking orientations were con-
sidered for further analysis.
Enzyme Inhibitor Interaction—The enzyme S. pneumoniae
hyaluronate lyase protein (Protein Data Bank code 1LOH),
which was the smaller of the two proteins, was kept flexible and
docked onto the HABP1 homotrimer, which was kept static.
Preprocessing of the hyaluronidase involved removal ofHAand
watermolecules. The receptor and ligandwere projected onto a
160-Å cubical grid using ZDOCK, a rigid body docking pro-
gram, followed by a refinement program, RDOCK. ZDOCK
uses a fast Fourier transform to search all possible binding
modes for the proteins, evaluating based on shape complemen-
tarity, desolvation energy, and electrostatics. The top 2000 pre-
dictions from ZDOCK were submitted to RDOCK where they
were minimized by CHARMM (Chemistry at Harvard Molec-
ular Mechanics) to improve the energies and eliminate clashes.
Finally the electrostatic and desolvation energies were recom-
puted byRDOCK, and the top ranking complexwas selected for
analysis of the contact interface.
RESULTS
In Vitro Effect of HABP1 on the Activity of SpnHL
The in vitro enzyme inhibition experiments demonstrated
that highly purified HABP1 inhibits SpnHL activity in a con-
centration-dependent manner as shown in Fig. 1. The activity
of purified SpnHL gradually decreased in the presence of
increasing concentrations of purified HABP1 either when
HABP1 was preincubated with HA and the reaction was initi-
ated with SpnHL or when it was preincubated with the enzyme
SpnHL and the reactionwas initiatedwithHA.This can be seen
much better in Fig. 1B, which shows a plot of percent inhibition
of SpnHL activity versus inhibitor concentration. HABP1 was
found to inhibit SpnHL with an IC50 value of 22 M.
FIGURE 1. Inhibition of SpnHL activity by HABP1 in a concentration-de-
pendentmanner. In A, the graph represents the inhibition of SpnHL activity
with increasing concentration of HABP1 as described under “Experimental
Procedures.” The first curve (F) represents HA preincubated with increasing
concentrationsofHABP1 (0–100M)before the reactionwas initiatedwith30
ngof the enzyme. The second curve (E) represents increasing concentrations
of HABP1 (0–100 M) preincubated with SpnHL (10 l of 3 ng/l) before the
reaction was initiated with 0.2 mg/ml HA. In both cases, activity was meas-
ured at 232 nm. In B, the graph represents the percent inhibition of SpnHL
activity as plotted against varying concentrations of inhibitor. The values rep-
resent the average of four different experiments.
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Structural Modeling: Binding of HA Hexasaccharide to HABP1
It has been reported that the alternate -1,4-glycosidic link-
age within HA gets cleaved by SpnHL (37), and we were inter-
ested in finding out whether HABP1 mediates SpnHL inhibi-
tion by protecting this bond during its interaction with HA. To
test this, we structurally modeled the HABP1 and HA interac-
tion. The results showed that binding of HA to HABP1 indeed
involves the -1,4-glycosidic linkage site on the HA oligomer,
explaining the observed reduction in enzyme activity.
Docking simulations depicted a steric fit between substrate
and inhibitor. Interestingly when the top ranking orientations
were analyzed to elucidate the molecular details of binding, the
HA hexasaccharide was predicted to bind with an energy of
7.59 kcal/mol, whereas the tetrasaccharide and disaccharide
HA oligomers showed binding energies of 6.56 and 6.28
kcal/mol, respectively. These observations are in agreement
with previous experimental reports stating that the HA hexas-
accharide shows better binding affinity than its shorter oli-
gomers (42). Fig. 2 shows the top ranking confirmation between
the hexasaccharide substrate and inhibitor after refinement as
described under “Experimental Procedures.” A total of 24 con-
tacts were observed between the sugar and HABP1 of which 17
were from chainA and sevenwere from chain B. Thus, only two
of the three polypeptide chains of HABP1 participate in this
interaction, and binding occurs at the junction of these two
chains. The hexasaccharide sugar
was found to bind with HABP1
strongly via hydrophobic as well as
hydrogen bond interactions. Inter-
estingly the two -1,4-glycosidic
linkages of the HA polymer (one
between HA1 and HA2 and the
other between HA2 and HA3) are
both entirely buried in this complex;
they are tethered on both sides by
hydrogen bonds as well as hydro-
phobic interactions. For example,
the C-1 and C-4 carbon atoms that
mediate the -1,4-glycosidic link-
ages are bound by multiple hydro-
phobic interactions with HABP1
residues His-75 and Thr-76 for the
first linkage and Asp-245, Arg-246,
and Gly-247 for the second linkage.
Furthermore residue Arg-122 of the
HA binding motif plays a key role in
the first linkage, making hydrogen
bonds with the glucuronate moiety
on the sugar preceding the linkage
and the secondary alcohol group on
the sugar succeeding the linkage.
Motif residues Arg-122 andAla-125
also participate in hydrophobic
interactions with the ligand. The
binding between HABP1 and the
HA hexasaccharide is further
strengthened by side chains of Lys-
80, Ser-106, and Arg-244 that make
hydrogen bonds with the sugar and Met-74, Gly-107, Asp-249,
and Thr-251 that are involved in hydrophobic interactions.
Atomic details of the all these interactions have been provided
in Table 1.
Thus the collective strength of a substantial number of non-
covalent interactions at the contact interface enhances the
binding of HA oligomers to HABP1, thereby protecting HA
from degradation. It may be noted that the inhibitor is in the
homotrimeric form, and the interaction causes a very small loss
of accessible surface area (479 Å2; roughly 2% of the entiremol-
ecule) at one of the three interchain junctions (see Fig. 2).
Therefore it is plausible that the remaining two interchain junc-
tions ofHABP1 could potentially bindmoreHAmolecules, or a
much longer HA polymer may utilize all three binding sites at
various regions along its length, ensuring protection.
Competitive Nature of SpnHL Inhibition by HABP1
To determine the nature of inhibition observed during the
preincubation of SpnHL and HABP1 (Fig. 1), enzyme assays
were carried out either in the absence or in the presence of
purified HABP1 (20 M). Fig. 3 depicts the plot of substrate
concentrations against the enzyme activity in the presence and
absence of inhibitor. An inhibition of 20–30% was observed in
the presence of the inhibitor. The plot shows that reaction was
linear over the time ofmeasurement, and the initial velocity and
FIGURE 2.Model of hyaluronan binding by HABP1. Each monomer of the HABP1 trimer has been shown in
distinct colors. ThedockedcomplexdepictsHAhexamer (shown inatomcolors) closelybound tooneof theHA
bindingmotifs (depicted in gray) on the trimeric HABP1 protein. The inset zooms into the complex to show the
details of the contact interface between the ligand and receptor. Hydrogen bonds are depicted as yellow
dashes. As can be seen, the -1,4-glycosidic linkage is protected during binding, being tethered by hydrogen
bonds and hydrophobic interaction on all sides.
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TABLE 1
Interactions and surface accessibility at the HABP1-HA hexasaccharide contact interface
For each HA unit, UA and NAc denote -D-glucuronic acid andN-acetyl--D-glucosamine, respectively. Stars (**) mark the C-1 and C-4 atoms that participate in the two
crucial -1,4-glycosidic linkages present in the HA hexasaccharide. Distance, distance in Å between interacting atoms from sugar and HABP1. RSA  (HA) is the loss in
residue surface accessibility (RSA) of HABP1 residues upon complexation with HAmeasured in Å2. “Hyp” denotes a hydrophobic interaction. RSA  (HL) shows the partial
a.s.a. lost from three residues of one chain of theHABP1 trimer during SpnHL inhibition. The last three rows depict residues that lose accessibility but do not directly interact
with the sugar. HA1, HA2, and HA3 denote the three hyaluronan units of the hexasaccharide. chn, chain; res, residue; id, identity; na, not applicable.
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other parameters were calculated as described under “Experi-
mental Procedures.” The Km was calculated to be 0.2765 and
0.41129 mM in the absence and presence of the inhibitor,
respectively. A Lineweaver-Burke plot (double reciprocal) of
the data obtained was indicative of competitive inhibition. The
value for Ki was obtained from plots of 1/V versus 1/[S]. It was
found thatHABP1 inhibits the enzyme at aKi value of 34.24M.
These results confirmed that the inhibition observed in Fig. 1 is
competitive in nature.
Structural Modeling: Inhibition of Hyaluronidase
Mediated by HABP1
To comprehend the molecular details and structural impli-
cations of the observed competitive inhibition, HABP1 was
docked with SpnHL as described under “Experimental Proce-
dures.” Analysis of the top ranking docking complex confirmed
that HABP1 binds to the enzyme in the same region where
substrate HA has been reported to bind (37); the data thus sup-
port the competitive inhibition observed in the experimental
assays.
Fig. 4Adepicts the overallmode of bindingwith the inset (Fig.
4B) showing the molecular details of the interaction. An acces-
sible surface area (a.s.a.) of2938 Å2 (roughly 11% of the total
a.s.a.) is buried on the negatively charged face of HABP1 trimer
upon binding to SpnHL, occluding an a.s.a. of 5489 Å2 (roughly
20% of total a.s.a.) from the enzyme around its active site cleft.
The majority of interactions at the contact interface emerge
from the juxtaposition of these two large and oppositely
charged surfaces. All three monomers of the inhibitor partici-
pate in binding. The refinedmodel of binding revealed a total of
207 contacts between the two structures mediated by 49 resi-
dues fromHABP1 and 81 residues fromSpnHL.Of these, 25 are
FIGURE 3. Lineweaver-Burke plot representing competitive nature of
inhibition. A, Michaelis-Menten graph. B, Lineweaver-Burke plot. In both
cases, curveE represents enzymeactivity in the absenceofHABP1 (0M), and
curve Œ represents 20–30% inhibition of enzyme activity in the presence of
HABP1 (20 M). The Km and Vmax values were calculated according to the
Lineweaver-Burke plot. Each plot is representative of at least more than four
separate experiments. The Kmwas calculated to be 0.2765 and 0.41129mM in
the absence and presence of the inhibitor, respectively. The inhibitor inhibits
the enzyme at a Ki value of 34.24 M.
FIGURE 4.HABP1binding to SpnHL. The enzyme SpnHL (green schematic) is
shown docked with the inhibitor HABP1 (trimer shown in silver schematic).
The active site is in the -domain of the enzyme; catalytic triad residues have
been labeled and depicted in orange ball-and-stick model. Residues of the
aromatic patch canbe seen inpink (dots inA and lines inB); thenegativepatch
in the active site is depicted in red (dots in A and lines in B). Non-covalent
interactions all along the contact interface are represented as dashed lines of
distinct colors, namely hydrogen bonds (yellow), electrostatic interactions
(blue), and hydrophobic interactions (cyan). Residues of both molecules
involved in these interactions are colored in the same color as the interaction.
(Onlymain chain carbonatomsare shown tomaintain clarity.) As canbe seen,
most of the interactions are electrostatic in nature. B is an enlarged inset of A.
Details are provided in the text.
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ionic interactions. The inhibitory activity ofHABP1 is evidently
due to the combined effect of the considerable number of non-
covalent interactions it forms with catalytically essential resi-
dues in the active site of the enzyme.
As can be seen in Fig. 4, the binding potency of the inhibitor
is a virtue of electrostatic, hydrophobic, and hydrogen bonding
interactions all along the contact interface mainly in the cata-
lytic pocket region and a few involving the -domain of the
enzyme. Several interesting features of the complex become
evident because the orientation of inhibitor obstructs the
region on the enzyme where substrate must enter and bind,
thereby rendering the cleft inaccessible. The majority of inter-
actions at the interface are electrostatic in nature. It may be
noted that the enzyme active site, which is in the form of a cleft
between the two structural domains of SpnHL, has a highly
positive center, and the negatively charged projection of
HABP1 plays a key role in facilitating the attachment, thereby
effecting the high charge complementarity at the interface. The
maximum ionic contacts are observed in the product release
region, which has previously been shown to be an important
target site for hyaluronidase inhibitors (27). Small molecule-
based inhibitor design strategies also target specific residues
within the active site that are known to be crucial for catalysis.
Targeting of these sites in the enzyme has been reported to add
to the potency of inhibition (43). These reports add strength to
our data because many of the reported crucial groups of resi-
dueswere observed to be blocked by the inhibitorHABP1 in the
final refined model as follows.
The Catalytic Triad—The side chain of the catalytically
active His-399 residue is blocked by close proximity to the
backbone and negative side chains of residue Asp-197 on the
inhibitor. As shown in Fig. 4, residues His-399 and Asn-349 of
the catalytic triad make electrostatic and hydrogen bond inter-
actionswith the inhibitor.His-399makes a hydrogen bondwith
Ser-201 of HABP1, whereas Asn-349 is involved in hydrogen
bonding with residue Asp-197. Although Tyr-408 does not
interact specifically with the inhibitor, it is within 5-Å distance
of the negative projection of HABP1 and thus rendered
solvent-inaccessible.
The Aromatic Patch—Residues Trp-291, Trp-292, and Phe-
343 of SpnHL are known to constitute the aromatic patch on
one end of the enzyme cleft, which has been reported to be
responsible for the correct positioning of substrate chains for
catalysis, i.e. for the selection of cleavage sites on the HA sub-
strate (27). Asp-197 of HABP1 completely obstructs this aro-
matic patch, making hydrophobic interactions with all three
patch residues. Trp-292makes additional hydrophobic interac-
tions with residues 198–200 of the inhibitor. Interactions
between other residues in the vicinity, namely Ile-296 and Gly-
297 from the enzyme and Ala-199 from the inhibitor, further
obstruct the surface accessibility of this patch. Overall these
interactions lead to a total loss of more than 75% residue
surface accessibility for the aromatic patch, thereby burying
it extensively.
The Positive and Negative Patches—The dense electrostatic
interactions at the binding interface depicted in Fig. 4 are
formed between the outermost residues of the catalytically
essential positive patch of the enzyme and the negative surface
of the inhibitor. For example, arginines 462 and 466 of this
patch lose 27 and 47 Å2 of their residue surface accessibility,
respectively, to ionic interactions with glutamates 198 and 200
of HABP1, amounting to a 77.4% loss of accessibility. Other
residues comprising the positive patch, namely Lys-250, Arg-
300, Arg-355, and Arg-480, also get buried during the inhibi-
tory interaction, resulting in an overall loss of 71% surface
accessible area for this patch. The negative patch comprising
residuesGlu-388, Asp-398, andThr-400 has been implicated in
the product release process of SpnHL. The above mentioned
interactions involving the positive patch of the enzyme also lead
to the occlusion of the residues in the negative patch because
the two patches lie in close vicinity of each other. In particular,
Glu-388 was observed to lose 12.5-Å2 (roughly 26%) surface
area during the interaction with HABP1.
It may be noted that the residues of the HA bindingmotif (of
HABP1) are not involved in any of its interactions with SpnHL.
Of the three potential HA binding sites on a given HABP1 tri-
mer, two are completely accessible during the inhibitory inter-
action. The third binding site shows a small overlap as three of
the 24 HABP1 residues required for sugar binding lose partial
side chain accessibility during the inhibitory interaction. These
three residues are shown in Table 1. A perusal of this partially
buried region reveals that the lost a.s.a. is relatively insignificant
(roughly 6%) as a result of which all three binding sites of
HABP1 retain sufficient accessibility when it mediates the inhi-
bition of SpnHL. The significance of this observation for the
mechanism of action is discussed below.
DISCUSSION
In the present study, we have characterized human HABP1
as the only known endogenous protein inhibitor of SpnHL, thus
implying indirectly its functional role in defense against bacte-
rial invasion. The mechanistic/structural aspects of this inhibi-
tion have been elucidated with the help of docking simulations.
HABP1 with an IC50 value of 22 M is one of the most potent
inhibitors of SpnHL reported to date. Ascorbic acid 6-hexade-
canoate has previously been reported as an inhibitor of S. aga-
lactiae hyaluronate lyase with an IC50 of 4 M, but it showed
much weaker inhibition of SpnHL with an IC50 of 100 M (27).
We have analyzed enzyme substrate interaction in context with
enzyme-inhibitor and substrate-inhibitor interactions to eluci-
date the structural details of the observed inhibition.
Preincubation of HABP1 and HA was able to inhibit the
enzyme activity, and there was no further degradation of HA
upon addition of SpnHL to the reaction solution. It was
observed that HA degradation and product release are totally
dependent on the ratio of HABP1 andHAmolecules present in
the reaction solution. With the increase in HABP1 concentra-
tion in the reaction solution, a decrease in enzymatic activity
was observed, whereas upon increasing the concentration of
HA, the enzymatic activity was retained. For a given amount of
HA, however, low HABP1 was not able to block enzyme or
sequester substrate, but with high concentration of HABP1,
95% inhibitionwas observed. Furthermore there was no change
in enzymatic activity when the concentration of HA was kept
equal to that of HABP1. It is therefore plausible that during the
preincubation binding occurred betweenHABP1 and its ligand
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HA, thereby protecting the latter from the enzyme. This deduc-
tion was structurally supported by docking experiments
between HABP1 and HA that revealed a tight binding with the
-1,4-glycosidic linkage of HA via hydrogen bonding as well as
hydrophobic interactions (shown in Fig. 2 and Table 1).
Having thus confirmed the protection of HA by HABP1, we
tested whether this was the exclusive mode of inhibition used
by the inhibitor. As shown in Fig. 1A, the inhibition of enzyme
observed uponpreincubating substrate and inhibitorwas found
to be comparable to the inhibition observed upon preincubat-
ing the enzyme and inhibitor. Subsequently assays were carried
out to determine the nature of this inhibition. As shown in Fig.
3, Lineweaver-Burke plot analysis confirmed that HABP1
inhibits SpnHL activity in a competitive manner. Docking
experiments between SpnHL and HABP1 further provided the
molecular details of the contact interface between HABP1 and
the active site cleft of SpnHL (Fig. 4). It was also observed that
HABP1 uses only the negative side/face of its trimeric (roughly
flat) structure during the inhibition of SpnHL. These observa-
tions were taken together to build a novel mechanism of
HABP1-mediated inhibition of SpnHL.
A Novel Mechanism for HABP1-mediated Inhibition of
SpnHL—The fascinating aspect of our study is that the sugar is
capable of binding to both enzyme and inhibitor, and in both
cases, it is the -1,4-glycosidic linkage of the sugar, which is
buried in the receptors. Rationalization of the competitive
nature of inhibition has further revealed that the enzyme
SpnHL binds to the substrate and inhibitor in the same region,
namely the active site cleft. It is remarkable that the doughnut-
shapedHABP1 acting as an inhibitor uses only its negative face/
side for blocking the enzyme, whereas the opposite side/face is
used for binding to the relatively negatively charged HA. Evi-
dently the inhibitor uses two distinct and spatially separate sites
for binding to the enzyme and the substrate. Based on these
observations from experiments as well as computational simu-
lations, we hypothesize thatHABP1mayuse a novel and unique
multipronged mechanism/model for lowering hyaluronidase
activity. According to this model, on one hand, HABP1
obstructs the active site of the enzyme to inhibit its activity,
thereby following the nature of competitive inhibition. On the
other hand, it uses its large free side/face to bind and sequester
up to three additional HA polymers from the matrix, thereby
protecting HA from SpnHL-mediated degradation during
infection. This model has been structurally depicted in Fig. 5.
Although one of the three inter chain junctions (or HA binding
sites) shows a slight loss of residue surface area during the
inhibitory interaction, 21 of 24 residues depicted in Table 1
remain fully accessible and free to bind HA oligomers. Alterna-
tively a single long polymer of HAmay bind to HABP1 using all
three of its binding sites to circumvent degradation.
Biological Implications—Our findings reveal that HABP1
interacts with and blocks a large number of crucial/conserved
groups of residues in the active site cleft of SpnHL.Amajority of
bacterial hyaluronate lyases are known to have a high degree of
sequence conservation in the cleft region, and consequently, we
speculate that theymay also be inhibited by HABP1 in a similar
manner. In contrast, mammalian and bacteriophage hyaluron-
idase enzymes have very different sequence as well as structural
architectures and are therefore not likely to be inhibited by
HABP1. It may be conjectured that this strategy of selective
defense against bacterial hyaluronidases may have evolved in
mammalian hosts to protect their own hyaluronidases from
inhibition. It is encouraging to note that there have been
reports of up-regulation and involvement of HABP1 in inflam-
mation, apoptosis, and bacterial infections like Listeria (44, 45).
Based on the crystal structure it has been suggested that termi-
nal -helices of HABP1 are critical for maintaining trimeric
assembly as well as protein-protein interactions (33, 46). This is
also evident from the Trp-Glu signature motif at the N-termi-
nal region ofHABP1 that is homologous to theWD-40 family of
proteins that play predominant roles in interprotein interac-
tions (47). A few viral proteins and bacterial proteins have
already been reported to interact with HABP1 (48). However,
although its multifunctional nature has been characterized, its
role in hyaluronan protection has never been explored before.
Apart from the ability to competitively inhibit bacterial hya-
luronidases, HABP1 has the added advantage of being able to
bind and sequester multiple HA oligomers by virtue of its
unique structural asymmetry. Our observations thus also
explain the inherent charge asymmetry of theHABP1 structure
that had not been accounted for until now. Itmay be speculated
that, at least to some extent, this characteristic may be used to
FIGURE 5. Proposed model for the multifaceted mechanism of HABP1-
mediated SpnHL inhibition. In this figure, multiple HA hexasaccharide
ligands (atom colors, stick representation) have been structurally superim-
posed upon the docked complex of enzyme and inhibitor (trimer shown in
gray). SpnHL has been colored by secondary structure (helices, red; sheets,
yellow; loops, green), and its active site has been depicted with HA oligomer
to highlight how the substrate binding region is entirely blocked by the one
side/faceof the inhibitor. SimilarlymultipleHAoligomershavebeendepicted
bound to the inhibitor to show that the three HA binding motif sites (green,
line representation) are free to bind substrate HA molecules even when one
entire side of the protein is blocking the SpnHL active site. Residues of the
enzyme and inhibitor within 5 Å of each other are depicted in blue and purple
lines. Hydrogen bonds are depicted as yellow dashes. The HA orientations
used for superimposition have been taken from the crystal structure (for
SpnHL), and the top ranking docked complexes are discussed in the text (for
HABP1).
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protect the hostHAmatrix fromendogenous hyaluronidases as
well.
Competitive inhibition conventionally refers to structural
analogy between substrate and inhibitor leading to competition
of both for the active site of the enzyme. It must be noted that
although we demonstrate the phenomenon of competitive
inhibition here the inhibitor is structurally distinct from the
substrate, and there is also a simultaneous blocking interaction
ofHABP1with its substrateHA. Such a dualmode of inhibition
is a unique phenomenon by itself, not previously demonstrated
by any other enzyme inhibitor. It is true that free unbridled
hyaluronidase activity would create much havoc, and nature
must have created a great number of mechanisms for keeping
these enzymes in check, mechanisms that must function at
multiple levels. We believe that the data presented in this work
may describe how remarkable such checking mechanisms can
be and that they may indeed function at multiple levels
simultaneously.
In conclusion, the identification of HABP1 as a competitive
inhibitor of SpnHL constitutes a new line of defense against
bacterial invasion and offers novel opportunities for therapeu-
tic intervention, making it a highly suitable candidate to be
investigated further for optimization of potency and specificity
against bacterial virulence factors. Furthermore based on the
insights obtained in this study, it will be possible to design short
inhibitory peptides for binding and protecting HA polymers.
Efforts in this direction present an alternative to synthetic
chemicals and are currently underway in our laboratory.
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